These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23259737)

  • 1. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
    Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
    J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
    Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
    Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
    J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
    Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
    Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland.
    Parczewski M; Leszczyszyn-Pynka M; Urbańska A
    Infect Genet Evol; 2017 Apr; 49():122-129. PubMed ID: 28017912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
    Ceccherini-Silberstein F; Van Baelen K; Armenia D; Trignetti M; Rondelez E; Fabeni L; Scopelliti F; Pollicita M; Van Wesenbeeck L; Van Eygen V; Dori L; Sarmati L; Aquaro S; Palamara G; Andreoni M; Stuyver LJ; Perno CF
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3938-48. PubMed ID: 20479206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
    Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
    PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
    Chehadeh W; Albaksami O; Al-Shammari S
    Antivir Chem Chemother; 2020; 28():2040206620927908. PubMed ID: 32434393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
    Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
    Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
    Charpentier C; Descamps D
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.